{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:30:42Z","timestamp":1772119842156,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:00:00Z","timestamp":1733529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:00:00Z","timestamp":1733529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100017959","name":"Health Commission of Hebei Province","doi-asserted-by":"publisher","award":["20210368"],"award-info":[{"award-number":["20210368"]}],"id":[{"id":"10.13039\/100017959","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Department of Finance of Hebei","award":["ZF2024130"],"award-info":[{"award-number":["ZF2024130"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s11096-024-01841-8","type":"journal-article","created":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T07:05:29Z","timestamp":1733555129000},"page":"382-391","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of combined proton pump inhibitors and posaconazole prophylaxis against invasive fungal infections in patients with hematologic malignancies: a retrospective study"],"prefix":"10.1007","volume":"47","author":[{"given":"Yan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruochen","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizhao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7692-9816","authenticated-orcid":false,"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,7]]},"reference":[{"issue":"16","key":"1841_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3238\/arztebl.2019.0271","volume":"116","author":"M Von Lilienfeld-Toal","year":"2019","unstructured":"Von Lilienfeld-Toal M, Wagener J, Einsele H, et al. Invasive fungal infection. Dtsch Arztebl Int. 2019;116(16):271\u20138. https:\/\/doi.org\/10.3238\/arztebl.2019.0271.","journal-title":"Dtsch Arztebl Int"},{"key":"1841_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2023.101215","volume":"94","author":"C Lass-Fl\u00f6rl","year":"2023","unstructured":"Lass-Fl\u00f6rl C, Steixner S. The changing epidemiology of fungal infections. Mol Aspects Med. 2023;94:101215. https:\/\/doi.org\/10.1016\/j.mam.2023.101215.","journal-title":"Mol Aspects Med"},{"issue":"1","key":"1841_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12929-023-00926-2","volume":"30","author":"W Fang","year":"2023","unstructured":"Fang W, Wu J, Cheng M, et al. Diagnosis of invasive fungal infections: challenges and recent developments. J Biomed Sci. 2023;30(1):42.\u00a0https:\/\/doi.org\/10.1186\/s12929-023-00926-2.","journal-title":"J Biomed Sci"},{"key":"1841_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2023.101190","volume":"92","author":"R Sprute","year":"2023","unstructured":"Sprute R, Nacov JA, Neofytos D, et al. Antifungal prophylaxis and pre-emptive therapy: when and how? Mol Aspects Med. 2023;92: 101190.\u00a0https:\/\/doi.org\/10.1016\/j.mam.2023.101190.","journal-title":"Mol Aspects Med"},{"issue":"4","key":"1841_CR5","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3390\/biomedicines11041063","volume":"11","author":"A Vitiello","year":"2023","unstructured":"Vitiello A, Ferrara F, Boccellino M, et al. Antifungal drug resistance: an emergent health threat. Biomedicines. 2023;11(4):1063.\u00a0https:\/\/doi.org\/10.3390\/biomedicines11041063.","journal-title":"Biomedicines"},{"key":"1841_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114967","volume":"199","author":"S Wu","year":"2023","unstructured":"Wu S, Song R, Liu T, et al. Antifungal therapy: novel drug delivery strategies driven by new targets. Adv Drug Deliv Rev. 2023;199:114967.\u00a0https:\/\/doi.org\/10.1016\/j.addr.2023.114967.","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"1841_CR7","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1007\/s10238-023-01062-9","volume":"23","author":"LR Soldi","year":"2023","unstructured":"Soldi LR, Coelho YNB, Paranhos LR, et al. The impact of antifungal prophylaxis in patients diagnosed with acute leukemias undergoing induction chemotherapy: a systematic review and meta-analysis. Clin Exp Med. 2023;23(7):3231\u201349.\u00a0https:\/\/doi.org\/10.1007\/s10238-023-01062-9.","journal-title":"Clin Exp Med"},{"issue":"5","key":"1841_CR8","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3390\/antibiotics12050884","volume":"12","author":"A Carmo","year":"2023","unstructured":"Carmo A, Rocha M, Pereirinha P, et al. Antifungals: from pharmacokinetics to clinical practice. Antibiotics (Basel). 2023;12(5):884.\u00a0https:\/\/doi.org\/10.3390\/antibiotics12050884.","journal-title":"Antibiotics (Basel)"},{"issue":"7","key":"1841_CR9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40265-020-01306-y","volume":"80","author":"L Chen","year":"2020","unstructured":"Chen L, Krekels EHJ, Verweij PE, et al. Pharmacokinetics and pharmacodynamics of posaconazole. Drugs. 2020;80(7):671\u201395.\u00a0https:\/\/doi.org\/10.1007\/s40265-020-01306-y.","journal-title":"Drugs"},{"issue":"1","key":"1841_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40265-022-01819-8","volume":"83","author":"L Chen","year":"2023","unstructured":"Chen L, Krekels EHJ, Heijnen AR, et al. An integrated population pharmacokinetic analysis for posaconazole oral suspension, delayed-release tablet, and intravenous infusion in healthy volunteers. Drugs. 2023;83(1):75\u201386.\u00a0https:\/\/doi.org\/10.1007\/s40265-022-01819-8.","journal-title":"Drugs"},{"issue":"8","key":"1841_CR11","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/jac\/dkad143","volume":"78","author":"J Stemler","year":"2023","unstructured":"Stemler J, Mellinghoff SC, Khodamoradi Y, et al. Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). J Antimicrob Chemother. 2023;78(8):1813\u201326.\u00a0https:\/\/doi.org\/10.1093\/jac\/dkad143.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1841_CR12","doi-asserted-by":"publisher","first-page":"14575","DOI":"10.1038\/s41598-020-71571-0","volume":"10","author":"TY Wong","year":"2020","unstructured":"Wong TY, Loo YS, Veettil SK, et al. Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients: a systematic review with meta-analysis and trial sequential analysis. Sci Rep. 2020;10(1):14575.\u00a0https:\/\/doi.org\/10.1038\/s41598-020-71571-0.","journal-title":"Sci Rep"},{"issue":"12","key":"1841_CR13","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1093\/jac\/dky286","volume":"73","author":"JA Maertens","year":"2018","unstructured":"Maertens JA, Girmenia C, Br\u00fcggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in \nLeukaemia. J Antimicrob Chemother. 2018;73(12):3221\u201330.\u00a0https:\/\/doi.org\/10.1093\/jac\/dky286.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"1841_CR14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/17425255.2020.1764939","volume":"16","author":"R Van Daele","year":"2020","unstructured":"Van Daele R, Spriet I, Maertens J. Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodyn\namic and clinical evaluation. Expert Opin Drug Metab Toxicol. 2020;16(7):539\u201350.\u00a0https:\/\/doi.org\/10.1080\/17425255.2020.1764939.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"1841_CR15","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1128\/AAC.00802-12","volume":"56","author":"MJ Dolton","year":"2012","unstructured":"Dolton MJ, Ray JE, Chen SC, et al. Multicenter study of posaconazole therapeutic drug monitoring: exposure\u2013response relationship and factors affecting concentration. Antimicrob Agents Chemother. 2012;56(11):5503\u201310.\u00a0https:\/\/doi.org\/10.1128\/AAC.00802-12.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1841_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/FTD.0000000000000952","volume":"44","author":"B Kably","year":"2022","unstructured":"Kably B, Launay M, Derobertmasure A, et al. Antifungal drugs TDM: trends and update. Ther Drug Monit. 2022;44(1):166\u201397.\u00a0https:\/\/doi.org\/10.1097\/FTD.0000000000000952.","journal-title":"Ther Drug Monit"},{"issue":"10","key":"1841_CR17","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/phar.2850","volume":"43","author":"EK McCreary","year":"2023","unstructured":"McCreary EK, Davis MR, Narayanan N, et al. Utility of triazole antifungal therapeutic drug monitoring: Insights from the Society of Infectious Diseases Pharmacists: endorsed by the Mycoses Study Group Education and Research Consortium. Pharmacotherapy. 2023;43(10):1043\u201350.\u00a0https:\/\/doi.org\/10.1002\/phar.2850.","journal-title":"Pharmacotherapy"},{"issue":"11","key":"1841_CR18","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","volume":"26","author":"A G\u00f3mez-L\u00f3pez","year":"2020","unstructured":"G\u00f3mez-L\u00f3pez A. Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation. Clin Microbiol Infect. 2020;26(11):1481\u20137.\u00a0https:\/\/doi.org\/10.1016\/j.cmi.2020.05.037.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"1841_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12879-018-3055-3","volume":"18","author":"L Chen","year":"2018","unstructured":"Chen L, Wang Y, Zhang T, et al. Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis. BMC Infect Dis. 2018;18(1):155.\u00a0https:\/\/doi.org\/10.1186\/s12879-018-3055-3.","journal-title":"BMC Infect Dis"},{"key":"1841_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.575463","volume":"11","author":"MM Jia","year":"2020","unstructured":"Jia MM, Zhang QW, Qin ZF, et al. Deciphering the relationship between the trough concentration of posaconazole and its efficacy and safety in Chinese patients with hematological disorders. Front Pharmacol. 2020;11:575463.\u00a0https:\/\/doi.org\/10.3389\/fphar.2020.575463.","journal-title":"Front Pharmacol"},{"key":"1841_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3389\/fmicb.2020.00349","volume":"11","author":"W Li","year":"2020","unstructured":"Li W, Xia F, Zhou H, et al. Efficacy of posaconazole prophylaxis for fungal disease in hematology patients treated with chemotherapy and transplantation: an open-label, prospective, observational study. Front Microbiol. 2020;11:349.\u00a0https:\/\/doi.org\/10.3389\/fmicb.2020.00349.","journal-title":"Front Microbiol"},{"issue":"6","key":"1841_CR22","doi-asserted-by":"publisher","first-page":"106995","DOI":"10.1016\/j.ijantimicag.2023.106995","volume":"62","author":"L Chen","year":"2023","unstructured":"Chen L, Krekels EHJ, Dong Y, et al. Meta-pharmacokinetic analysis of posaconazole following dosing of oral suspension, delayed-release tablet, and intravenous infusion in patients vs. healthy volunteers: Impact of clinical characteristics and race. Int J Antimicrob Agents. 2023;62(6):106995.\u00a0https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106995.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"1841_CR23","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367\u201376.\u00a0https:\/\/doi.org\/10.1093\/cid\/ciz1008.","journal-title":"Clin Infect Dis"},{"key":"1841_CR24","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury. LiverTox: Clinical and Research Information on Drug-Induced Liver [Internet]. [Updated 2019 May 4]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548069\/"},{"issue":"7","key":"1841_CR25","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/mmy\/myaa106","volume":"59","author":"M Kraljevic","year":"2021","unstructured":"Kraljevic M, Khanna N, Medinger M, et al. Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients. Med Mycol. 2021;59(7):701\u201311.\u00a0https:\/\/doi.org\/10.1093\/mmy\/myaa106.","journal-title":"Med Mycol"},{"issue":"4","key":"1841_CR26","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/bjh.19116","volume":"203","author":"G Reynolds","year":"2023","unstructured":"Reynolds G, Urbancic KF, Fong CY, et al. Invasive fungal infection following venetoclax and posaconazole co-administration. Br J Haematol. 2023;203(4):593\u20138.\u00a0https:\/\/doi.org\/10.1111\/bjh.19116.","journal-title":"Br J Haematol"},{"issue":"7","key":"1841_CR27","doi-asserted-by":"publisher","first-page":"e02230","DOI":"10.1128\/AAC.02230-17","volume":"62","author":"HJ Suh","year":"2018","unstructured":"Suh HJ, Yoon SH, Yu KS, et al. The genetic polymorphism UGT1A4*3 is associated with low posaconazole plasma concentrations in hematological malignancy patients receiving the oral suspension. Antimicrob Agents Chemother. 2018;62(7):e02230\u2013e2317.\u00a0https:\/\/doi.org\/10.1128\/AAC.02230-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1841_CR28","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1111\/bcp.13707","volume":"84","author":"PG Cojutti","year":"2018","unstructured":"Cojutti PG, Candoni A, Lazzarotto D, et al. Co-administration of proton pump inhibitors and\/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies. Br J Clin Pharmacol. 2018;84(11):2544\u201350.\u00a0https:\/\/doi.org\/10.1111\/bcp.13707.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1841_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/myc.13020","volume":"63","author":"J Oh","year":"2020","unstructured":"Oh J, Kang CI, Kim SH, et al. Antifungal prophylaxis with posaconazole tablet and oral suspension in patients with haematologic malignancy: therapeutic drug monitoring, efficacy and risk factors for the suboptimal level. Mycoses. 2020;63(1):89\u201394.\u00a0https:\/\/doi.org\/10.1111\/myc.13020.","journal-title":"Mycoses"},{"issue":"6","key":"1841_CR30","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1007\/s15010-023-02078-9","volume":"51","author":"C K\u00f6nig","year":"2023","unstructured":"K\u00f6nig C, G\u00f6pfert M, Kluge S, et al. Posaconazole exposure in critically ill ICU patients: a need for action. Infection. 2023;51(6):1767\u201372.\u00a0https:\/\/doi.org\/10.1007\/s15010-023-02078-9.","journal-title":"Infection"},{"issue":"8","key":"1841_CR31","doi-asserted-by":"publisher","first-page":"ofad389","DOI":"10.1093\/ofid\/ofad389","volume":"10","author":"K Benedict","year":"2023","unstructured":"Benedict K, Gold JAW, Toda M, et al. Low rates of antifungal therapeutic drug monitoring among inpatients who received itraconazole, posaconazole, or voriconazole, United States, 2019\u20132021. Open Forum Infect Dis. 2023;10(8):ofad389.\u00a0https:\/\/doi.org\/10.1093\/ofid\/ofad389.","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"1841_CR32","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1080\/14740338.2022.2047177","volume":"21","author":"R O'Flynn","year":"2022","unstructured":"O\u2019Flynn R, Zhou YP, Waskin H, et al. Hepatic safety of the antifungal triazole agent posaconazole: characterization of adverse event reports in a manufacturer\u2019s safety database. Expert Opin Drug Saf. 2022;21(8):1113\u201320.\u00a0https:\/\/doi.org\/10.1080\/14740338.2022.2047177.","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"1841_CR33","doi-asserted-by":"publisher","first-page":"myad079","DOI":"10.1093\/mmy\/myad079","volume":"61","author":"K Jensen","year":"2023","unstructured":"Jensen K, Saleh OA, Chesdachai S, et al. Association of adverse effects with high serum posaconazole concentrations. Med Mycol. 2023;61(8):myad079.\u00a0https:\/\/doi.org\/10.1093\/mmy\/myad079.","journal-title":"Med Mycol"},{"key":"1841_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.697330","volume":"12","author":"YL Yang","year":"2021","unstructured":"Yang YL, Xiang ZJ, Yang JH, et al. Adverse effects associated with currently commonly used antifungal agents: a network meta-analysis and systematic review. Front Pharmacol. 2021;12:697330.\u00a0https:\/\/doi.org\/10.3389\/fphar.2021.697330.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1841_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14826","volume":"37","author":"DC Sabatino","year":"2023","unstructured":"Sabatino DC, Lange NW, Salerno DM, et al. Elevated posaconazole trough concentrations are not associated with increased risk for posaconazole toxicity in lung transplant recipients. Clin Transplant. 2023;37(1):e14826.\u00a0https:\/\/doi.org\/10.1111\/ctr.14826.","journal-title":"Clin Transplant"},{"issue":"10","key":"1841_CR36","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/cid\/ciaa119","volume":"71","author":"RW Parker","year":"2020","unstructured":"Parker RW, Ferr\u00e9 EMN, Myint-Hpu K, et al. Posaconazole-induced pseudohyperaldosteronism manifesting with nephrotic-range proteinuria. Clin Infect Dis. 2020;71(10):2768\u201370.\u00a0https:\/\/doi.org\/10.1093\/cid\/ciaa119.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1841_CR37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/kjm2.12325","volume":"37","author":"J Tantiprawan","year":"2021","unstructured":"Tantiprawan J, Sunthornyothin S, Boonchaya-Anant P, et al. Posaconazole-induced pseudohyperaldosteronism. Kaohsiung J Med Sci. 2021;37(3):253\u20134.\u00a0https:\/\/doi.org\/10.1002\/kjm2.12325.","journal-title":"Kaohsiung J Med Sci"},{"issue":"12","key":"1841_CR38","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1093\/cid\/ciz741","volume":"70","author":"MH Nguyen","year":"2020","unstructured":"Nguyen MH, Davis MR, Wittenberg R, et al. Posaconazole serum drug levels associated with pseudohyperaldosteronism. Clin Infect Dis. 2020;70(12):2593\u20138.\u00a0https:\/\/doi.org\/10.1093\/cid\/ciz741.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"1841_CR39","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/cid\/ciaa119","volume":"71","author":"RW Parker","year":"2020","unstructured":"Parker RW, Ferr\u00e9 EMN, Myint-Hpu K, et al. Posaconazole-induced pseudohyperaldosteronism manifesting with nephrotic-range proteinuria. Clin Infect Dis. 2020;71(10):2768\u201370. https:\/\/doi.org\/10.1093\/cid\/ciaa119.","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01841-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-024-01841-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01841-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T16:46:03Z","timestamp":1742316363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-024-01841-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,7]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1841"],"URL":"https:\/\/doi.org\/10.1007\/s11096-024-01841-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4326408\/v1","asserted-by":"object"}]},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,7]]},"assertion":[{"value":"27 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors confirm that the funding had no influence on the study results. There are no conflicts of interest associated with this publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}